Skip to Main Content

Paper Details

Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA.
Nat Med
56
2022
CDR3, HLA, HLA anchor, HLA)-A*03:01 allele, HLA-bound neopeptide, NeoAg, PIK3CA, PIK3CA hotspot mutation, PIK3CA-mutant tumors, T cell, T cell receptor, TCR, TCR-engineered T cells, TCRs, cancer, driver oncogenes, human, human leukocyte antigen, malignancies, mice, mutant PIK3CA, neopeptide/HLA complex, patients, tumor, wild-type PIK3CA, wild-type PIK3CA tumors
Author NameAffiliation
Chaitanya BandlamudiMarie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Hannah Y WenMemorial Sloan Kettering Cancer Center
Britta WeigeltMemorial Sloan Kettering Cancer Center
Paul Zumbo
Paul Zumbo
Arnaud Da Cruz PaulaMemorial Sloan Kettering Cancer Center
Alexander DrilonMemorial Sloan Kettering Cancer Center
Alexander Drilon
Alexander DrilonMemorial Sloan Kettering Cancer Center
Brian M BakerUniversity of Notre Dame
Brian M BakerHarper Cancer Research Institute, University of Notre Dame
  • 1 - 11

Datasets

Release 1.2